GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Selling, General, & Admin. Expense

Cosmo Pharmaceuticals NV (XSWX:COPN) Selling, General, & Admin. Expense : CHF3.5 Mil (TTM As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cosmo Pharmaceuticals NV's selling, general, & admin. expense for the six months ended in Jun. 2023 was CHF9.6 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2023 was CHF3.5 Mil.


Cosmo Pharmaceuticals NV Selling, General, & Admin. Expense Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Selling, General, & Admin. Expense Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.91 10.76 4.85 2.92 3.50

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.03 -4.72 9.91 -6.03 9.56

Competitive Comparison of Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense falls into.



Cosmo Pharmaceuticals NV Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF3.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (XSWX:COPN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Cosmo Pharmaceuticals NV Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines